Skip to main content
    M

    Matinas BioPharma Holdings Inc (MTNB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $0.88
    -0.04 (-4.56%)

    Market Cap: $881,570

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Matinas BioPharma Holdings Inc (MTNB) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Matinas BioPharma Holdings (MTNB) has a market cap of $881,570. It holds $1.94M more cash than debt, 219.49% of its market cap.

    Total Valuation

    Market Cap$881,570
    Latest price (Nov 17, 2026)$0.88

    Key Dates

    The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 29, 2027 (expected)
    Last Earnings DateNov 16, 2026
    Fiscal Year EndDecember

    Valuation Ratios

    P/E Ratio0.9x
    P/B Ratio0.3x
    P/TBV Ratio1.5x

    Price Statistics

    The stock is down 95.17% over 52 weeks and trades 57.69% below its 50-day average.

    Beta (1Y)0.26
    52-Week Change-95.17%
    1-Month Change-46.70%
    3-Month Change-75.53%
    6-Month Change-89.41%
    5-Year Change-99.82%
    10-Year Change-99.86%
    Total Return (1Y)-95.17%
    Total Return (3Y CAGR)-82.86%
    Total Return (5Y CAGR)-74.36%
    Max Drawdown (1Y)-95.00%
    Max Drawdown (3Y)-99.68%
    Sharpe Ratio (1Y)-2.28
    Correlation with SPY (1Y)0.03
    50-Day Average$2.08
    200-Day Average$6.46
    52-Week Range$0.81 to $17.40
    RSI (14 Days)26.9
    Average Volume (20 Days)55.96K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.78x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio1.78x
    Quick Ratio1.78x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on invested capital is -187.86% and return on equity is -236.48% over the last 12 months.

    Return on Equity (ROE)-236.48%
    Return on Assets (ROA)-158.12%
    Return on Invested Capital (ROIC)-187.86%

    Scores

    MTNB has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Gross Profit$85.00K
    Operating Income-$6.83M
    Pretax Income-$6.93M
    Net Income-$6.92M
    EBITDA-$6.45M
    Reported EPS (TTM)$1.01

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 66.89% of the $4.38M in total assets.

    Cash and Equivalents$1.94M
    Total Debt$1.00K
    Net Cash$1.94M
    Net Cash Per Share$1.74
    Working Capital$926.00K
    Shareholder Equity$2.93M
    Book Value Per Share$2.63
    Tangible Book Value$668.00K
    Tangible Book Per Share$0.60
    Total Assets$4.38M
    Total Liabilities$1.45M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$6.56M
    FCF Per Share-$6.70
    Depreciation and Amortization$515.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Dividends and Yields

    MTNB does not pay a dividend.

    Earnings Yield111.11%
    Buyback Yield-286.46%
    Shareholder Yield-286.46%

    Stock Splits

    The last split was a 1-for-15 reverse split on Sep 28, 2026.

    Last Split DateSep 28, 2026
    Split TypeReverse split
    Split Ratio1:15

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About MTNB

    What is MTNB's market cap?

    Matinas BioPharma Holdings has a market cap of $881,570.

    What is MTNB's P/E ratio?

    Matinas BioPharma Holdings has a trailing P/E ratio of 0.9x.

    How many shares of MTNB are outstanding?

    Matinas BioPharma Holdings has 1.11M shares outstanding.

    Does MTNB pay a dividend?

    No. Matinas BioPharma Holdings does not pay a dividend.

    How much debt does MTNB have?

    Matinas BioPharma Holdings has $1.00K of total debt and $1.94M of cash and equivalents, a net cash position of $1.94M.